Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded up 37.9% during mid-day trading on Friday . The company traded as high as C$0.24 and last traded at C$0.20. 1,160,600 shares changed hands during trading, an increase of 120% from the average session volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Up 37.9 %
The firm has a 50 day moving average price of C$0.09 and a 200 day moving average price of C$0.07. The stock has a market cap of C$17.42 million, a PE ratio of -10.00 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Zymeworks in Focus for Insider Activity: Catalysts Ahead
- High Flyers: 3 Natural Gas Stocks for March 2022
- Kura Sushi Stock Dips Into a Hot Buying Opportunity
- The How and Why of Investing in Gold Stocks
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
